Detection of *Giardia lamblia* stool samples: a comparison of two enzyme-linked immunosorbent assays [version 1; peer review: 1 approved, 1 approved with reservations]

Tomas Jelinek¹, Stefan Neifer²

¹Berlin Centre for Travel and Tropical Medicine, Berlin, 10117, Germany
²Labor für medizinische Mikrobiologie und Tropenmedizin, Berlin, 13353, Germany

**Abstract**

Two commercially produced enzyme-immunosorbent assays (EIAs) to detect antigens of *Giardia lamblia* in stool specimens, Ridascreen Giardia and Serazym Giardia, were evaluated. A total of 88 stool specimens were collected from patients who presented for various medical complaints in our outpatient clinic. Every specimen was examined by a conventional microscopic examination (CME), PCR and tested by both EIA kits. When microscopy was used as the reference standard, the Ridascreen Giardia showed a sensitivity of 72.9% and a specificity of 100%. Serazym Giardia had a sensitivity of 93.8% and a specificity of 100%. Antigen detection by EIA has been established as a valuable tool to make parasite stool diagnostics more effective.

**Keywords**

Giardia lamblia diagnosis, antigen detection

---

**How to cite this article:** Jelinek T and Neifer S. Detection of *Giardia lamblia* stool samples: a comparison of two enzyme-linked immunosorbent assays [version 1; peer review: 1 approved, 1 approved with reservations] F1000Research 2013, 2:39
https://doi.org/10.12688/f1000research.2-39.v1

First published: 11 Feb 2013, 2:39
https://doi.org/10.12688/f1000research.2-39.v1
### Introduction

Intestinal parasites have a world-wide distribution. One of the most common intestinal protozoan parasites is *Giardia lamblia*. Since it has a fecal-oral transmission cycle and is contracted by ingestion of contaminated water or food or by person-to-person contact, the highest disease burden is found in areas where sanitary conditions are poor. The highest rates of infection are therefore encountered in developing countries (10–30% in young children), while in developed countries, infections occur mostly in persons living in closed communities, homosexual men, immigrants and, of increasing importance, travellers returning from highly endemic countries (2–5% of symptomatic patients)\(^1\).

The protozoan flagellate *Giardia lamblia* has a reported global prevalence of approximately 30% in cases of acute or persistent diarrhea\(^2\). Acute giardiasis has been repeatedly described in travellers returning from highly endemic areas\(^3\). The infection may be asymptomatic or present with various symptoms. The main symptom is watery, foul smelling diarrhoea, often accompanied by nausea, abdominal cramps or gurgling, bloating and weight loss\(^4\). Symptoms of variable severity may persist for weeks. *Giardia lamblia* does not invade the tissue\(^5\). Its life cycle consists of two different stages: the trophozoite and the infectious form (the cyst).

The diagnosis of giardiasis is frequently based on microscopical detection of the organisms in stool samples. Yet the method is time and labour intensive and depends on the skill of an experienced microscopist\(^6\). Diagnosis via microscopical examination of a single stool specimen has a low sensitivity and may therefore miss up to 50% of *Giardia* infections\(^7\). Because of the intermittent shedding of the parasites, microscopic examination of three consecutive stool specimens is required to reach a sensitivity of over 90%\(^8\). Given these difficulties the development of sensitive, cost-effective and rapid diagnostic methods is of utmost importance. Enzyme immuno-assays (EIAs) for detection of the specific antigens in stools have developed into an efficient diagnostic technique in the detection of *Giardia lamblia*\(^9\).

In this study we tested two commercially available EIA kits that detect antigens of *Giardia lamblia* in stool samples (Ridascreen Giardia; manufactured by r-biopharm, and Serazym Giardia; manufactured by Seramun Diagnostica). The results were compared with those of a conventional microscopic examination (CME), immunofluorescence microscopy (IFM) and with polymerase chain reaction (PCR).

### Materials and methods

Institutional ethical approval was obtained before the study. After written informed consent was obtained, stool specimens were collected from patients who presented for diarrhoea plus various other complaints. All patients were German nationals returning from vacations abroad. All stool samples were investigated for ova and parasites by direct microscopy (iron-hematoxylin stain) and the SAF (sodium-acetate-acetic acid-formaline)/ethyl acetate-concentration technique\(^10\). Every slide was read for at least 10 min by two experienced microscopists (conventional microscopy examination, CME) before being considered negative if no ova or parasites could be detected within this time. A part of every fresh stool sample was stored immediately at –20°C and tested later by EIA, according to the relevant manufacturer’s instructions, by one lab technician who was not aware of the results of the microscopy or polymerase chain reaction (PCR) findings. PCR was performed at the Bernhard Nocht Institute for Tropical Medicine, Hamburg (Professor Egbert Tannich) by investigators who were blinded to the results of the EIA and microscopy tests. If different results between the EIA, PCR or microscopy (CME) were obtained, immunofluorescence microscopy was used for additional confirmation of true positive results. EIA results were compared with those obtained by conventional microscopic examination (CME), immunofluorescence microscopy (IFM) and by PCR. The samples that had a positive result in CME and/or immunofluorescence microscopy were considered true positives. The sensitivity, specificity and the positive predictive value (PPV) of both EIAs were calculated. These values were also calculated for PCR against microscopy, and also for both EIAs against PCR.

### Results

The 88 specimens were examined by CME, IFM, PCR and two EIAs. *Giardia lamblia* was detected in 44 (54.5%) of stool samples by both, CME and IFM. Comparing the Ridascreen Giardia EIA against microscopy, 35 stool samples were positive and 40 were negative with both methods (Table 1). Sensitivity of the test against CME and IFM was 72.9%, whilst the specificity was 100%. With the Serazym Giardia test, sensitivity was calculated at 93.8% (45 samples positive), with a specificity of 100%. PCR produced several false negative results against CME and IFM, which are considered the gold standard tests. The sensitivity of PCR was 85.4% (41 samples correctly positive), whilst the specificity was 100% (Table 2). With PCR used as a background for the EIAs, results became more divergent (Table 3): Ridascreen Giardia performed with a sensitivity of 73.2% and a specificity of 83.4%, while Serazym Giardia showed a sensitivity of 95.1%, and a specificity of 87.2%.

### Discussion

In order to find simple, inexpensive and reliable diagnostic techniques for detecting intestinal infections with *Giardia lamblia*, several EIA test kits have been developed and tested in various studies\(^4\). In this study, we evaluated the performance of two commercially available EIA kits for detecting *Giardia lamblia* antigens. We tested 88 specimens and compared the results of EIA to the results of stool microscopy (CME and IFM) of the same sample. When microscopy was used as the reference standard, the EIA kits both showed a specificity of 100%, while...
PCR showed a lower sensitivity than one of the EIAs (85.4% vs. 93.8% Serazym Giardia). This may be explained by the high concentration of DNase in stool samples that traditionally hamper PCR diagnostics from this material\(^{18}\). It is important to notice though that the use of PCR as gold standard for the evaluation of EIAs in this setting would have produced false low specificity results for both tests (Table 3: 83.4% for Ridascreen, and 87.2% for Serazym, as opposed to the actual 100% specificities in both tests against CME and IFM).

As mentioned earlier, microscopic examination of one single stool specimen has a low sensitivity\(^7,9\). It has been demonstrated that antigens of *Giardia lamblia* can be detected by EIA even in the absence of intact organisms (cysts or trophozoites). This may result in a greater sensitivity of EIA-tests compared with microscopy\(^9\) and therefore provide low specificity results when only one CME is used as a reference standard. In a study conducted by Aldeen \textit{et al.}\(^{16}\), nine different immunoassay kits for the detection of *Giardia lamblia* were evaluated: the sensitivity ranged from 93% to 100% and the specificity in all EIAs was above 99%. The authors suggest that the high specificity results are due to the examination of up to seven individual slide preparations on an initially negative microscopic finding. In conclusion, we found that the EIAs evaluated are highly sensitive and specific for detection of *Giardia lamblia*. In our setting, one of the two EIAs proved to be more reliable than PCR. Antigen detection by EIA methods certainly has developed into a powerful additional method for increasing the effectiveness of stool diagnostics. Results of this study also demonstrate that considerable differences in sensitivity might occur between commercial tests. Thus, careful selection of appropriate test kits seems mandatory. For screening purposes, the antigen tests remain additional tools: there is currently no replacement for microscopical examination of stool specimens, since other potential pathogens could otherwise escape detection.

### Author contributions
TJ designed the study, collected part of the samples, did part of the testing, and wrote part of the paper. SN collected part of the samples, did part of the testing and wrote part of the paper. Both authors approved the final manuscript for publication.

### Competing interests
No competing interests have been disclosed.

### Grant information
The authors declare that no grants were involved in supporting this work.

### Acknowledgements
Sekisui Virotech GmbH provided the Serazym Giardia assays as well as financial support for purchase of the Ridascreen Giardia assays and for PCR.

| Table 1 Results of Ridascreen Giardia and and Serazym Giardia tests against conventional and immunofluorescence stool microscopy. |
|---|
| **Antigen test** | **Microscopy** | **Positive** | **Negative** |
| Ridascreen Giardia | Positive | 35 | 0 |
| | Negative | 13 | 40 |
| Serazym Giardia | Positive | 45 | 0 |
| | Negative | 3 | 40 |
| Sensitivity Ridascreen Giardia 72.9%. |
| Specificity Ridascreen Giardia 100%. |
| Positive predictive value Ridascreen Giardia 100%. |
| Negative predictive value Ridascreen Giardia 75.5%. |
| Sensitivity Serazym Giardia 93.8%. |
| Specificity Serazym Giardia 100%. |
| Positive predictive value Serazym Giardia 100%. |
| Negative predictive value Serazym Giardia 93%. |

| Table 2 Results of PCR against conventional and immunofluorescence stool microscopy. |
|---|
| **PCR** | **Microscopy** | **Positive** | **Negative** |
| | Positive | 41 | 0 |
| | Negative | 7 | 40 |
| Sensitivity PCR 85.4%. |
| Specificity PCR 100%. |
| Positive predictive value PCR 100%. |
| Negative predictive value PCR 85.1%. |

| Table 3 Results of Ridascreen Giardia and Serazym Giardia tests against PCR. |
|---|
| **Antigen test** | **PCR** | **Positive** | **Negative** |
| Ridascreen Giardia | Positive | 30 | 5 |
| | Negative | 11 | 42 |
| Serazym Giardia | Positive | 39 | 6 |
| | Negative | 2 | 41 |
| Sensitivity Ridascreen Giardia 73.2%. |
| Specificity Ridascreen Giardia 83.4%. |
| Positive predictive value Ridascreen Giardia 85.7%. |
| Negative predictive value Ridascreen Giardia 79.2%. |
| Sensitivity Serazym Giardia 95.1%. |
| Specificity Serazym Giardia 87.2%. |
| Positive predictive value Serazym Giardia 86.7%. |
| Negative predictive value Serazym Giardia 95.4%. |

Sensitivity varied considerably (Table 1). Ridascreen Giardia showed 72.9%, whilst Serazym Giardia performed considerably better with a sensitivity of 93.8%. PCR detection of Giardia DNA was also compared to microscopy (Table 2). Interestingly,
References

1. Ali SA, Hill DR: *Giardia intestinalis*. Curr Opin Infect Dis. 2003; 16: 453–60.
2. Pawlowski SW, Warren CA, Guerrant R: Diagnosis and treatment of acute or persistent diarrhea. Gastroenterology. 2009; 136: 1874–1886.
3. Huang DB, White AC: An updated review on *Cryptosporidium* and *Giardia*. Gastroenterol Clin North Am. 2006; 35: 291–314.
4. Jelinek T, Peyerl G, Löscher T, et al: Giardiasis in travellers: evaluation of an antigen-capture ELISA for the detection of *Giardia lamblia*-antigen in stool. Z Gastroenterol. 1996; 34: 237–240.
5. Weitzel T, Dittrich S, Möhl I, et al: Evaluation of seven commercial antigen detection tests for *Giardia* and *Cryptosporidium* in stool samples. Clin Microbiol Infect. 2006; 12: 656–659.
6. Benzeguir AK, Aust KA: Evaluation of an enzyme-immunoassay test kit for diagnosing infections with *Entamoeba histolytica*. Arch Med Res. 1997; 28: 276–278.
7. Addis DG, Mathews HM, Stewart JM, et al: Detection of *Giardia lamblia* and *Entamoeba histolytica* in stool samples by two enzyme immunoassays. Eur J Clin Microbiol Infect Dis. 2001; 20: 389–391.
8. Goldin AJ, Hall A, Sarker RN, et al: Diagnosis of *Giardia lamblia* infection in Bangladeshi infants: fecal antigen capture EIA. Trans R Soc Trop Med Hyg. 1993; 87: 428–432.
9. Aldeen WE, Carroll K, Robison A, et al: Comparison of nine commercially available enzyme-linked immunosorbent assays for detection of *Giardia lamblia* in fecal specimens. J Clin Microbiol. 1996; 34: 1338–1340.
10. Nantavisai K, Mungthin M, Tan-araya P, et al: Evaluation of the sensitivities of DNA extraction and PCR methods for detection of *Giardia duodenalis* in stool specimens. J Clin Microbiol. 2007; 45: 581–583.
11. Elkadi IA, Smith DH, Hommel M: Early diagnosis of giardiasis by faecal antigen detection using capture EIA in a cohort of children in the United Arab Emirates. Trans R Soc Trop Med Hyg. 1992; 86: 520–521.
12. Rosenblatt JE, Sloan LM, Schneider SK: Evaluation of an enzyme-linked immunosorbent assay for the detection of *Giardia lamblia* in stool specimens. Diagn Microbiol Infect Dis. 1993; 16: 337–341.
13. Pillai DR, Keaystone JS, Sheppard DC, et al: *Entamoeba histolytica* and the diagnostic methods in a setting of nonendemicity. Clin Infect Dis. 1999; 29: 1315–1318.
14. Troeger H, Epple HJ, Schneider T, et al: Effect of chronic *Giardia lamblia* infection on epithelial transport and barrier function in human duodenum. Gut. 2007; 56: 328–335.
15. Addis DG, Mathews HM, Stewart JM, et al: Evaluation of a commercially available enzyme-linked immunosorbent assay for *Giardia lamblia* antigen in stool. J Clin Microbiol. 1991; 29: 1137–1142.
16. Anonymous. Instruction Sheet DYS004. Parasitology. Fixatives, Reagents and Stains. http://www.diasys.com/PDF/DYS004–StainsReagentsFix.pdf (last accessed 21 JAN 2013).
17. Ali SA, Hill DR: *Giardia intestinalis*. Curr Opin Infect Dis. 2003; 16: 453–60.
18. Pawlowski SW, Warren CA, Guerrant R: Diagnosis and treatment of acute or persistent diarrhea. Gastroenterology. 2009; 136: 1874–1886.
19. Huang DB, White AC: An updated review on *Cryptosporidium* and *Giardia*. Gastroenterol Clin North Am. 2006; 35: 291–314.
20. Jelinek T, Peyerl G, Löscher T, et al: Giardiasis in travellers: evaluation of an antigen-capture ELISA for the detection of *Giardia lamblia*-antigen in stool. Z Gastroenterol. 1996; 34: 237–240.
21. Weitzel T, Dittrich S, Möhl I, et al: Evaluation of seven commercial antigen detection tests for *Giardia* and *Cryptosporidium* in stool samples. Clin Microbiol Infect. 2006; 12: 656–659.
22. Benzeguir AK, Aust KA: Evaluation of an enzyme-immunoassay test kit for diagnosing infections with *Entamoeba histolytica*. Arch Med Res. 1997; 28: 276–278.
23. Addis DG, Mathews HM, Stewart JM, et al: Detection of *Giardia lamblia* and *Entamoeba histolytica* in stool samples by two enzyme immunoassays. Eur J Clin Microbiol Infect Dis. 2001; 20: 389–391.
24. Goldin AJ, Hall A, Sarker RN, et al: Diagnosis of *Giardia lamblia* infection in Bangladeshi infants: fecal antigen capture EIA. Trans R Soc Trop Med Hyg. 1993; 87: 428–432.
25. Aldeen WE, Carroll K, Robison A, et al: Comparison of nine commercially available enzyme-linked immunosorbent assays for detection of *Giardia lamblia* in fecal specimens. J Clin Microbiol. 1996; 34: 1338–1340.
26. Nantavisai K, Mungthin M, Tan-araya P, et al: Evaluation of the sensitivities of DNA extraction and PCR methods for detection of *Giardia duodenalis* in stool specimens. J Clin Microbiol. 2007; 45: 581–583.
Open Peer Review

Current Peer Review Status: ✅ ❓

Version 1

Reviewer Report 12 June 2013

https://doi.org/10.5256/f1000research.312.r999

© 2013 Lowe S. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Selwyn Lowe
Maastricht University Medical Center, Maastricht, The Netherlands

Abstract: The PCR is mentioned, but not the results compared to the standard.

Article content:

- **Materials and methods:** "Every slide was read for at least 10 min by two experienced microscopists ..." Was this done in parallel for 2 different slides or sequentially for 1 slide? If sequentially, microscopy was done for 20 min and this could influence the results.
- If different results between the EIA, PCR or microscopy (CME) were obtained, was immunofluorescence microscopy used for additional confirmation of true positive results? This is not in line with the Results: The 88 specimens were examined by CME, IFM, PCR and two EIA's.
- Please clarify the difference between what is stated in the Materials and Methods section and in the Results section. Where all 5 assays performed on all 88 stool samples?
- **Results:** It is not quite clear how the different assays compare to each other. Maybe a 5 by 5 table with only the positive results would give a better insight?

**Competing Interests:** No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Reviewer Report 14 February 2013

https://doi.org/10.5256/f1000research.312.r771
© 2013 López-Vélez R. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Rogelio López-Vélez
Tropical Medicine and Clinical Parasitology, Infectious Diseases Department, Ramón y Cajal Hospital, Madrid, Spain

**Competing Interests:** No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com